AngioSafe, Inc.

AngioSafe® is redefining revascularization through the development of technologies that safely, efficiently, and predictably empower interventionalists to tackle complex lesions. Its proprietary Atheroplasty™ core technology platform does not require any capital equipment and simultaneously combines mechanisms and features to revascularize severely occluded arteries, simplifying one of the most complex procedures in cardiovascular interventions.

With its flagship Santreva™-ATK endovascular revascularization catheter, AngioSafe is advancing a new era of vascular innovation to improve procedure outcomes and confidence for physicians addressing complex femoropopliteal interventions.

Santreva-ATK is FDA cleared and CE marked and is now commercially available.